Maria Pia Morelli

Medicine & Life Sciences

1. ErbB Receptors 100%
2. Colorectal Neoplasms 87%
3. Neoplasms 73%
4. Monoclonal Antibodies 46%
5. Cetuximab 43%
6. AZD 6244 34%
7. N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine 33%
8. Cell Line 33%
9. Non-Small Cell Lung Carcinoma 30%
10. Polysaccharides 29%
11. Vascular Endothelial Growth Factor Receptor 27%
12. Therapeutics 26%
13. Protein-Tyrosine Kinases 25%
14. Bortezomib 25%
15. Clinical Trials, Phase I 25%
16. Vascular Endothelial Growth Factor A 23%
17. Cell-Free Nucleic Acids 22%
18. Erlotinib Hydrochloride 22%
19. Pharmaceutical Preparations 18%
20. tremelimumab 18%
21. belinostat 18%
22. Heterografts 18%
23. Antibodies, Monoclonal, Humanized 17%
24. cediranib 17%
25. Mutation 17%
26. Growth 17%
27. Lung Neoplasms 16%
28. Protein-Arginine N-Methyltransferases 15%
29. Vascular Endothelial Growth Factor Receptor-3 15%
30. Survival 15%
31. Drug Therapy 15%
32. Circulating Tumor DNA 14%
33. Butylated Hydroxytoluene 14%
34. Vorinostat 14%
35. Colonic Neoplasms 14%
36. Cell Adhesion Molecule-1 14%
37. Angiogenesis Inhibitors 14%
38. Blocking Antibodies 14%
39. Vascular Endothelial Growth Factor Receptor-1 13%
40. Gefitinib 13%
41. Carcinoembryonic Antigen 13%
42. Proteasome Endopeptidase Complex 12%
43. Inbred NOD Mouse 12%
44. Sorafenib 12%
45. Intensity-Modulated Radiotherapy 12%
46. Proteasome Inhibitors 12%
47. Gastrointestinal Neoplasms 12%
48. Microwaves 12%
49. Histone Deacetylases 12%
50. Pancreatic Neoplasms 11%